8-K: Viking Therapeutics Announces Positive 52-Week Data for NASH Treatment VK2809

Viking Therapeutics reports positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, showing significant improvements in NASH resolution and fibrosis.

Summary

• Viking Therapeutics announced positive 52-week results from its Phase 2b VOYAGE study of VK2809 for treating Non-Alcoholic Steatohepatitis (NASH).
• The study met its primary endpoint, showing statistically significant reductions in liver fat content at week 12.
• Secondary endpoints at 52 weeks showed that up to 75% of patients treated with VK2809 achieved NASH resolution without worsening of fibrosis, compared to 29% for placebo.
• Up to 57% of VK2809-treated patients achieved a 1-stage improvement in fibrosis without worsening of NASH, compared to 34% for placebo.
• Additionally, up to 48% of VK2809-treated patients achieved both NASH resolution and a 1-stage improvement in fibrosis, compared to 20% for placebo.
• VK2809 also demonstrated significant reductions in liver fat content at Week 52, with mean relative changes from baseline ranging from 37% to 55%.
• The drug also showed reductions in LDL-C, triglycerides, and other atherogenic proteins, suggesting potential cardio-protective benefits.
• The safety profile of VK2809 was encouraging, with most adverse events being mild or moderate and similar to placebo.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 2b trial, with significant improvements across multiple endpoints and a favorable safety profile. This suggests a high likelihood of success in future trials and a strong potential for commercialization.

Positives

• VK2809 demonstrated statistically significant improvements in NASH resolution and fibrosis.
• The drug showed significant reductions in liver fat content at both 12 and 52 weeks.
• VK2809 exhibited a favorable safety and tolerability profile, with minimal differences compared to placebo.
• The study results were consistent across various sensitivity analyses, indicating the robustness of the efficacy signal.
• VK2809 showed reductions in LDL-C and other atherogenic proteins, suggesting potential cardio-protective benefits.

Negatives

• One treatment-related serious adverse event (SAE) was reported, involving a worsening of psychiatric symptoms in a patient with a history of psychiatric disorders.
• While most treatment arms showed reductions in ALT and AST levels, not all achieved statistically significant improvement compared to placebo.

Risks

• The study reported one treatment-related serious adverse event, which could raise concerns about the drug's safety profile.
• Not all treatment arms achieved statistically significant improvements in ALT and AST levels compared to placebo, which may require further investigation.
• The long-term effects and safety of VK2809 beyond 52 weeks are not yet known.

Future Outlook

The company looks forward to sharing the full results at a future medical meeting and continues to develop VK2809 and other therapies for metabolic and endocrine disorders.

Management Comments

• Brian Lian, Ph.D., chief executive officer of Viking, stated that the data provide compelling evidence of VK2809's efficacy in patients with biopsy-confirmed NASH and fibrosis.
• He also noted that treatment with VK2809 led to statistically significant improvements across key histologic endpoints, including fibrosis, supporting the value of thyroid hormone receptor beta agonism as an important mediator of disease.
• Management highlighted the excellent tolerability profile of VK2809, with low rates of GI disturbances and treatment-related adverse events.

Industry Context

The results are significant in the context of the NASH treatment landscape, where effective therapies are still needed. The positive data for VK2809 positions it as a potential best-in-class treatment for NASH, a disease with a high unmet medical need.

Comparison to Industry Standards

• The results of the VK2809 study compare favorably to other NASH treatments in development, particularly in terms of the percentage of patients achieving NASH resolution and fibrosis improvement.
• For example, some other NASH therapies have shown lower rates of NASH resolution and fibrosis improvement in Phase 2 trials.
• The safety profile of VK2809 also appears competitive, with low rates of GI disturbances compared to some other treatments.
• The reduction in LDL-C and other atherogenic proteins is a potential differentiator for VK2809, as many other NASH treatments do not offer this additional benefit.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results, potentially leading to an increase in the company's stock price.
• Patients with NASH may benefit from a new and effective treatment option.
• The positive results could attract potential partners or investors, further supporting the company's development efforts.

Next Steps

• The company plans to share the full results at a future medical meeting.
• Viking will continue to develop VK2809 and other therapies for metabolic and endocrine disorders.

Key Dates

Keywords

VK2809, NASH, Non-Alcoholic Steatohepatitis, Fibrosis, Liver Fat, Thyroid Hormone Receptor Beta Agonist, VOYAGE Study, Metabolic Disorders, LDL-C, Lipid Disorders